GAIN THERAPEUTICS INC (GANX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.80-1.10%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GANX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 66.5% |
| Our one-year growth estimate | diamond | 1.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 65.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GANX — litigation filed
Dated 2026-07-16
Other Events. On July 16, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release and shareholder letter in which it announced, among other things, that its current cash and cash equivalents are anticipated to fund the Company’s operations into the second quarter of 2027, based on current operating plans, including the completion of the Phase 1b open-label extension in October 2026 and initiation of a Phase 2 clinical study during the third quarter of 2026. Cautionary Note Regard…
Why it matters: Updates on cash reserves will show financial health. This affects investor confidence and funding for trials.
Worry ifCash and equivalents are reported to last until Q2 2027 without more funding.
Less concerning ifCash reserves are expected to run out before Q2 2027. This suggests possible funding issues.
Why it matters: Results will provide insights into the drug's effectiveness and safety. This could impact future trials.
Watch forThe results show a big improvement in MDS-UPDRS scores.
Also watch forThe results show no big change in MDS-UPDRS scores.
Why it matters: FDA clearance is crucial for starting the Phase 2 study of GT-02287. This could advance treatment for Parkinson's disease.
Supportive ifFDA grants IND clearance for GT-02287 by the end of Q2 2026.
Worry ifFDA denies or delays IND clearance for GT-02287 beyond Q2 2026.
Why it matters: Completion will confirm the durability of treatment effects. This is crucial for moving to Phase 2.
Supportive ifAll participants finish the nine-month study of GT-02287.
Worry ifSome people leave the nine-month study early.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$225 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $768 loss on $10,000 · 7.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,196 loss on $10,000 · 62.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Results from the Phase 1b study will provide insights into GT-02287's effectiveness. This could impact future development.
Watch forThe Phase 1b study of GT-02287 had positive results. It showed significant clinical improvement.
Also watch forThe Phase 1b study had negative results. It showed no clinical improvement.
Why it matters: Completing the Phase 1b extension will confirm if GT-02287 works and is safe for Parkinson's patients.
Supportive ifCompletion of the Phase 1b extension with stable MDS-UPDRS scores reported.
Worry ifAny delays or issues in completing the Phase 1b extension.
Why it matters: This analysis is key for moving forward with the Phase 2 study. Delays could slow progress.
Supportive ifThe company completes the 90-day analysis by the end of Q3 2026.
Worry ifThe analysis is delayed beyond Q3 2026.
Why it matters: Finishing this extension is important. It will help collect long-term data on GT-02287. This data will guide future studies and regulatory submissions.
Supportive ifThe nine-month extension of the Phase 1b study will finish on time in October 2026.
Worry ifThe nine-month extension of the Phase 1b study is late or not finished by October 2026.
Why it matters: Starting the Phase 2 trial is important for rexaceract in treating Parkinson's. This could show it can change the disease.
Supportive ifThe Phase 2 trial begins in Q3 2026 as planned after FDA IND clearance.
Worry ifThe Phase 2 trial does not start as scheduled, indicating possible delays or issues.
Why it matters: Selecting an indication for GT-04686 could enhance Gain's pipeline and long-term value. This shows progress in drug development.
Supportive ifThe first therapeutic indication for GT-04686 should be chosen by the end of 2026.
Worry ifIf no choice is made by year-end, it could slow down development.
Why it matters: Final results will give key data on how well rexaceract works and its safety. This could change future plans.
Watch forFinal results from the Phase 1b study are expected in Q4 2026. They should show positive outcomes.
Also watch forResults show no real improvement or safety issues. This affects future trials.